EORTC 22033-26033
EORTC 22033 asked whether temozolomide could replace radiotherapy as the first treatment for high-risk low-grade glioma and found no difference in progression-free survival, with the molecular subtype mattering more than the choice of treatment.
Overview
EORTC 22033-26033 randomised 477 adults with high-risk low-grade glioma to 50.4 Gy radiotherapy or dose-dense temozolomide for up to a year. Median progression-free survival was 46 months with radiotherapy and 39 months with temozolomide (hazard ratio 1.16, not significant); IDH-mutant tumours without 1p/19q co-deletion did better with radiotherapy, and health-related quality of life did not differ (Baumert and colleagues, Lancet Oncology 2016). Radiotherapy followed by chemotherapy (as in RTOG 9802) remains the standard.
Similar pages
not linked directly; found by shared links- TrialEORTC 26951
Shares Brain and spinal cord tumours (all types), IMRT / IGRT (modern external beam), Glioma & glioblastoma and the tag radiation-wave4.
- TrialRTOG 9402
Shares Brain and spinal cord tumours (all types), IMRT / IGRT (modern external beam), Glioma & glioblastoma and the tag radiation-wave4.
- TrialCATNON (EORTC 26053-22054)
Shares Brain and spinal cord tumours (all types), Temozolomide, IMRT / IGRT (modern external beam), Glioma & glioblastoma.
- TrialPOP-RT
Shares IMRT / IGRT (modern external beam) and the tag radiation-wave4.
- TrialRTOG 9601
Shares IMRT / IGRT (modern external beam) and the tag radiation-wave4.
- TrialHORRAD
Shares IMRT / IGRT (modern external beam) and the tag radiation-wave4.
- TrialCAO/ARO/AIO-94 (German Rectal Cancer Study)
Shares IMRT / IGRT (modern external beam) and the tag radiation-wave4.
- TrialNCIC MA.20
Shares IMRT / IGRT (modern external beam) and the tag radiation-wave4.